Treatment-emergent side effects often affect adherence to aromatase inhibitor (AI) therapy. In the present study, we examined the sleep patterns and daytime function both objectively using actigraphy and subjectively using validated questionnaires in women receiving AI therapy. Daytime function significantly decreased after 3 months of AI therapy and correlated with increased fatigue. Larger studies are necessary to understand why daytime function is affected by AI therapy and to identify interventions to improve daytime function, which could be helpful in improving adherence to AI therapy. Introduction: Adherence to aromatase inhibitor (AI) therapy is poor, often because of treatment-emergent side effects, including musculoskeletal symptoms, fatigue, and insomnia. In the present analysis, we examined the sleep patterns and daytime function both objectively using actigraphy and subjectively using validated questionnaires in women initiating AI therapy. Patients and Methods: Postmenopausal women with stage 0-III hormone receptor-positive breast cancer who were initiating AI therapy were eligible. The patients wore actigraphy devices for 10 consecutive days and completed questionnaires at baseline before the initiation of AI and after 3 months of AI therapy. Associations between the baseline demographics and symptoms, changes in patient-reported outcomes and actigraphy measures from baseline to 3 months of AI therapy and discontinuation of AI therapy were examined using sign tests, logistic regression models, Spearman's correlation, and linear mixed models. Results: Forty-two patients (86%) completed the baseline assessments and 23 patients (47%) completed both the baseline and the 3-month assessments. Objectively measured daytime function as measured by total daytime activity decreased during the 3 months after starting AI (232,566 activity count vs. 204,205 activity count; P ¼ .023), and the decrease was more evident in women with higher baseline physical function. Reduced daytime activity correlated with increased fatigue (r ¼ À0.49; P ¼ .017). Conclusion: Daytime function decreased after initiation of AI therapy and correlated moderately with increased fatigue, although no association was identified with changes in pain or sleep quality. Additional studies are required to understand why function is reduced, which could have implications for interventions to improve patient tolerance of, and persistence with, AI therapy.
Introduction
Aromatase inhibitor (AI) therapy is commonly used for adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer. New data have emerged favoring extended endocrine therapy for > 5 years for women with early-stage breast cancer. 1 However, despite these data, 50% of women discontinue treatment before 5 years. 2, 3 Poor adherence and persistence with endocrine therapy have been associated with worse breast cancer-related mortality. [4] [5] [6] Treatment-emergent toxicity is a key reason for early treatment discontinuation. In the multicenter prospective randomized ELPh (Exemestane and Letrozole Pharmacogenetics) trial of postmenopausal women with early-stage breast cancer, 32.4% of patients discontinued initial AI therapy within 2 years, with a median time to treatment discontinuation of 6 months. 7 Of the patientreported reasons for discontinuation during treatment, AI-associated musculoskeletal syndrome (AIMSS) was the primary reason for treatment discontinuation, with fatigue and insomnia the next leading causes. 7 Women with poor sleep quality before AI initiation were more likely to discontinue therapy because of toxicity by 1 year compared with women with good sleep quality. 8 It is unknown how or whether AIMSS affects fatigue and insomnia and daytime activity. Most studies reporting the effect of AI therapy on sleep have relied on subjective assessment with patient-reported outcomes. Previously, objective assessment required polysomnography, which remains the reference standard for the assessment of sleep; however, this is burdensome and costly. More recently, studies have demonstrated that actigraphy, an objective measurement used to quantify sleep and circadian rhythms, has a high correlation with polysomnography. During the past 2 decades, the use of actigraphy has gained popularity because it uses a noninvasive method, is low cost, and provides accurate sleep measurements in an ambulatory or home setting. 9, 10 Although changes in sleep quality have been previously reported using objective and subjective assessments in breast cancer patients undergoing surgery, chemotherapy, and radiation, reported studies evaluating changes in daytime function and sleep disturbance using actigraphy and validated surveys of patients receiving AI therapy are lacking.
In the present study, we examined the changes in daytime function and sleep parameters in patients receiving AI therapy both objectively using actigraphy and subjectively using validated questionnaires. We hypothesized that symptoms from AI therapy would interfere with daytime function and sleep for a subset of treated patients. In addition, we hypothesized that patients with worsening daytime function and/or sleep disturbance over time would be more likely to discontinue AI therapy.
Patients and Methods

Study Participants
The participants were recruited from December 2013 through February 2016 at the University of Michigan Comprehensive Cancer Center. Postmenopausal women with stage 0-III hormone receptor-positive breast cancer who had completed all indicated surgery, radiation therapy, and chemotherapy and were initiating treatment with an AI were eligible for enrollment. Patients who had previously received tamoxifen therapy were permitted to enroll. Those with sleep apnea requiring continuous positive airway pressure, restless leg syndrome requiring medication for treatment, previous treatment with an AI, a history of medical or arthritic disease that would interfere with evaluation of pain or activity level, the use of a wheelchair for ambulation most of the time, or those working second or third shifts with nontraditional sleep schedules were excluded from the present study. The institutional review board at the University of Michigan approved the clinical trial (ClinicalTrials.gov identifier, NCT01983995), and patients provided written informed consent before undergoing study-related procedures.
Study Procedures
Before initiation of AI therapy, enrolled patients wore the actigraphy device for 10 consecutive days and completed validated questionnaires, as described. The patients then initiated AI therapy with anastrozole 1 mg daily, exemestane 25 mg daily, or letrozole 2.5 mg daily. The choice of AI medication was at the discretion of the treating physician. Three months after initiation of AI therapy, the patients again wore the actigraphy device for 10 consecutive days and completed the same validated questionnaires.
Outcome Measures
Actigraphy. Daytime activity and sleep were assessed using the wrist-worn Actiwatch Spectrum Pro accelerometer (Philips Healthcare, Bend, OR). This device is an omnidirectional accelerometer that records the acceleration changes at a frequency of 32 times per second and stores the data as "activity counts" per 30-second sampling period. The parameters used to evaluate daytime activity included total daytime activity (sum of all valid activity counts), average daytime activity per minute, daytime maximum activity (the highest valid activity count obtained), immobile time, and variability in activity. The daytime activity parameters were measured as activity counts during awake hours, and immobile time was measured as minutes of presumed rest predefined by the actigraphy algorithm during daytime hours. Daytime maximum activity and variability in activity were used to characterize the maximum activity performed and the changes in activity during daytime hours, respectively.
Sleep quality was assessed using the following parameters: total sleep time, sleep time during night hours, waking after sleep onset, total activity at night, and sleep efficiency. The total sleep time and waking after sleep onset (during time in bed) were determined by the actigraphy sleep algorithm. A sleep diary was used in conjunction with actigraphy to verify the sleep and wake times and to record pain levels and the use of sleep aids. Total activity at night was defined as predefined movement captured by the accelerometer during night time hours, and sleep efficiency was defined as the time asleep divided by the time in bed.
Questionnaires
Each patient completed validated questionnaires at baseline and 3 months after initiation of AI therapy. The PROMIS sleep disturbance, PROMIS fatigue, and PROMIS physical function questionnaires are 8-item, 7-item, and 10-item questionnaires, respectively, developed by the National Institutes of Health roadmap initiative PROMIS (available at www. NIHPROMIS.org) used to characterize sleep and physical function in those with and without sleep disorders. Raw scores are translated to a T-score, with a mean score of 50 and a 10-point standard deviation. Higher scores represent a greater amount of the quantity being measured (eg, more sleep disturbance, better physical function).
The Functional Assessment of Cancer TherapyeEndocrine Subscale is a 47-item questionnaire used to measure the quality of life and side effects of endocrine treatment in patients with breast cancer. It assesses 4 quality-of-life domains (physical, emotional, social/family, and functional well-being) and 19 items that measure symptoms commonly related to endocrine therapy. Higher scores reflect better quality of life. It has been validated in women with breast cancer and has good testeretest reliability. 15 The Brief Pain Inventory is a 17-item patient self-rating scale that assesses sensory and reactive components of pain. For the sensory components, it addresses severity, location, chronicity, and degree of relief resulting from therapy. For the reactive components, it assesses depression, suffering, and perceived availability of relief. 19 It has been validated in patients with both cancer and noncancer pain. 16, 17 Higher scores reflect more pain or pain interference.
Statistical Analysis
The primary objective of the study was to characterize the changes in daytime function and sleep patterns through actigraphy and validated questionnaires in women receiving AI therapy. Significant changes from baseline to 3 months in the actigraphy parameters and patient-reported symptoms were assessed using sign tests. Pairwise associations among the baseline patient demographics, baseline patient symptoms, changes in patient symptoms, and changes in actigraphy were examined using Spearman correlation coefficients. Changes in measures were computed as the difference in the observed value at month 3 and baseline visits. For the actigraphy measures collected daily during the 10-day reporting period, the mean of each measure was used to summarize each visit.
The McNemar and sign tests were performed to evaluate whether a significant difference was present in the proportion of women taking sleep medications and the number of sleep medications used at baseline and after 3 months of AI therapy, respectively. Sleep medications were defined as any medication used to induce sleep, such as sedatives (ie, benzodiazepines), hypnotic agents (ie, zolpidem tartrate), or other sleep aids (ie, melatonin, diphenhydraminecontaining products).
A chronologic association between sleep and daytime activity was assessed using linear mixed model scaling, with transformation of the outcome variables, if needed. In separate models, we evaluated sleep and daytime activity bidirectionally as both predictors and outcomes. Specifically, sleep efficiency and sleep time at night were the variables of interest to quantify sleep, and total activity and average activity per minute were of interest to quantify daytime activity. All mixed models included a fixed visit effect and random subject effect and assessed the addition of the sleep or daytime activity predictor using a c 2 test of nested models. Logistic regression was used to assess the associations between binary outcomes, including discontinuation of therapy and the use of previous chemotherapy, with baseline patient characteristics and changes in both actigraphy and patient-reported symptoms. Discontinuation of therapy was defined as discontinuation of the AI for > 14 days, including women who temporarily withheld AI therapy for ! 14 days before resuming AI.
The threshold for statistical significance was prespecified as a P value of < .05, and no correction was made for multiple comparisons owing to the small sample size and exploratory nature of the analysis.
Results
Patient Characteristics
Of the 49 enrolled patients, 42 (86%) completed baseline assessments and 23 (47%) completed both the baseline and the 3-month assessments (Figure 1 ). Eighteen patients had incomplete 3-month assessments owing to discontinuation of AI therapy before the 3-month point (n ¼ 5), incomplete actigraphy data (n ¼ 2), or had withdrawn for personal reasons (n ¼ 11). The participants were predominantly white (94%) with stage I disease (71%; Table 1 ). In addition to undergoing surgical resection, 14 patients received neoadjuvant or adjuvant chemotherapy (29%) and 29 patients (59%) underwent adjuvant radiation therapy. Seven patients (14%) had previously received tamoxifen. All but 2 enrolled patients had started treatment with anastrozole (96%).
Changes in Actigraphy and Patient-reported Symptoms During AI Therapy
Daytime function as measured by total daytime activity exhibited a significant overall decrease between baseline and 3 months after starting AI therapy (232,566 activity count [AC] vs. 204,205 AC; P ¼ .023; Table 2 ). Of the 24 patients with paired baseline and 3-month total AC, 5 patients (21%) had a modest 10% to 20% reduction in total daytime activity and 8 (33%) had a substantial > 20% decrease in activity. However, the activity level for 6 patients Effect of AI Therapy on Sleep and Activity in Early-stage BC (25%) remained relatively stable, and 5 (21%) had an increased total activity level of ! 10%. Also, a trend was seen toward reduced daytime maximum activity (1075 AC vs. 960 AC; P ¼ .06; Figure 2 ) during the 3-month period. No statistically significant differences between visits were found in daytime average activity per minute, variability in activity, or immobile time. In addition, no statistically significant changes were found in any sleep parameters during the first 3 months of AI therapy. During the first 3 months of AI therapy, a statistically significant increase in mean worst pain (baseline, 1.38; 3-month, 2.17; P ¼ .035) and a trend toward an increase in mean average pain (baseline, 0.87; 3-month, 1.27; P ¼ .09; Table 3 ) were found. No significant changes were found in any other patient-reported symptoms during the 3-month period. Sleep medications were used by 9 women at baseline and 12 women after 3 months of AI therapy; this difference was not statistically significant.
No temporal association was found between sleep and daytime activity. The previous night's sleep quality (sleep efficiency and total sleep at night) was not found to affect activity the next day (P ¼ .66 and P ¼ .11, respectively). Similarly, activity on a given day (total activity during the day and average daytime activity per minute) was not found to affect that night's sleep quality (P ¼ .31 and P ¼ .80, respectively).
Associations Between Baseline Patient Characteristics and Changes in Actigraphy or Patient-reported Symptoms
Patients with greater physical function at baseline experienced a larger decrease in daytime function after the first 3 months of AI therapy. Moderate-to-strong correlations between baseline physical function as measured using the PROMIS physical function scale and total daytime activity (Spearman correlation coefficient r ¼ À0.64; P ¼ .001), daytime average activity per minute (r ¼ À0.70; P ¼ .0002), and variability in activity (r ¼ À0.68; P ¼ .0003) were identified (Supplemental Table 1 ; available in the online version). In addition, a moderately strong correlation was found between age and change in total sleep time from baseline to 3 months of AI therapy, with older patients experiencing a larger decrease in total sleep time (r ¼ À0.43; P ¼ .039; Supplemental Table 2 ; available in the online version). Furthermore, a moderate positive correlation was found between a lower body mass index (BMI) and a greater decrease in daytime activity with 3 months of AI therapy (r ¼ 0.48; P ¼ .017). No associations were found between previous chemotherapy or other baseline patient-reported symptoms with changes in actigraphy (Supplemental Table 3 ; available in the online version; and data not shown).
Age was also associated with a change in pain interference over time. Older patients experienced less pain interference from baseline to 3 months after initiation of AI (r ¼ À0.40; P ¼ .039; Supplemental Table 4 ; available in the online version). No correlations were found between the baseline BMI and changes in patient-reported symptoms during AI therapy, and no association was found between previous chemotherapy and changes in patient symptoms during AI therapy. Patient-reported physical function, as assessed by PROMIS physical function, was moderately to strongly positively correlated with changes in daytime function, as assessed using multiple parameters (Table 4) . A larger reduction in patient-reported physical function correlated with a larger reduction in total daytime activity (r ¼ 0.61; P ¼ .0026), daytime average activity per minute (r ¼ 0.69; P ¼ .0004), and variability in activity (r ¼ 0.51; P ¼ .016). In addition, an increase in physical function from baseline to 3 months was associated with a larger decrease in total sleep time (r ¼ À0.63; P ¼ .0018) and immobile time during daytime hours (r ¼ À0.56; P ¼ .006).
Patient-reported fatigue assessed by PROMIS fatigue was moderately negatively correlated with changes in daytime function and moderately positively correlated with changes in total sleep time (Table 5) . Women with more fatigue at 3 months compared with baseline had a larger decrease in daytime activity (r ¼ À0.49; P ¼ .017) and daytime average activity per minute (r ¼ À0.48; P ¼ .020) at 3 months after AI initiation. Patients with more fatigue at 3 months compared with at baseline also had a larger increase in total sleep time at 3 months compared with baseline (r ¼ 0.38; P ¼ .08). Changes in patient-reported symptoms of sleep disturbance, sleep quality, symptoms from endocrine therapy, and pain were not associated with changes in actigraphy daytime or sleep variables.
Discontinuation of AI Therapy
Of the 49 enrolled patients, 13 (26.5%) discontinued AI therapy between enrollment and November 2016. No associations were found between discontinuation of therapy and baseline patient characteristics, including age, BMI, baseline patient-reported symptoms, and actigraphy variables. Similarly, no associations were found between discontinuation of AI therapy at any time and changes in any of these variables during the first 3 months of AI therapy. Effect of AI Therapy on Sleep and Activity in Early-stage BC
Discussion
In the present analysis of the effects of AI therapy on daytime activity and sleep disturbance, we used both actigraphy measures and validated subjective questionnaires to thoroughly evaluate the changes in both daytime activity and sleep quality in women receiving AI therapy. Our findings suggest that AI therapy can negatively affect patients' daytime activity without a statistically significant change in sleep patterns. In addition, this decrease in physical activity did not appear to be related to persistent effects of previous therapy. These results have implications for patient treatment and the development of strategies to improve persistence with AI therapy.
As expected, pain modestly worsened after the initiation of AI therapy. Although it is possible that an increase in pain might have contributed to a decrease in daytime activity, we were unable to find such an association in our cohort. Alternatively, other factors such as fatigue also likely contributed to the decreased activity, as demonstrated by the strongly negative correlation between the change in fatigue and daytime activity parameters during the 3 months after the initiation of AI therapy. It is unknown whether patients experienced increased fatigue, which led them to reduce their activity levels, or whether the decreased activity resulted in more fatigue. It is also unclear whether this was independent of pain or sleep disturbance, although patients experiencing fatigue might subsequently experience more pain because of inactivity. However, guidelines have recommended physical activity as a key intervention for managing chronic fatigue in cancer patients. 20 In addition, a randomized phase III trial demonstrated that moderate exercise can improve pain in women with AIMSS. Therefore, proactively encouraging patients to be more active could potentially lead to improved therapy tolerance and increased persistence with therapy. 21 Although musculoskeletal symptoms have been clearly shown to be a primary cause of premature discontinuation of AI therapy, it is unknown what role other potentially modifiable symptoms such as sleep disturbance might have. Although we hypothesized that sleep quality would worsen during AI therapy, in this relatively small study, we were unable to identify any associations between AI discontinuation and changes in either objective assessment of sleep quality or sleep disturbance with actigraphy or patient-reported sleep symptoms. This is in contrast to the findings of larger studies that relied on patient-reported symptoms. 8, 22 We also examined the temporal relationship between daytime activity and sleep quality. However, we were unable to demonstrate an effect on the previous night's sleep quality on the subsequent day's activity or an effect of the daytime activity on sleep quality the following night. Therefore, the magnitude of the effect of sleep disturbance on AI-associated symptoms and persistence with therapy remains poorly defined. We closely examined the associations between actigraphy measures and patient-reported symptoms to determine whether actigraphy provided additional insight into daytime activity and sleep quality in women receiving AI therapy. The use of actigraphy failed to add substantially to the patient-reported assessment of activity because a high correlation was found between changes in PROMIS physical function and the objectively assessed changes in daytime activity. In contrast, the changes in the other subjective and objective sleep quality assessments were not as highly correlated. Although we might be able to rely on patient-reported symptoms for routine evaluation of daytime function, it is difficult to determine the role of objective versus subjective measures for the examination of sleep quality in women receiving AI therapy based on the findings from the present study, in part because of the low variability in sleep measures across patients and time points using the different methods. In addition, specific instances exist in which objective measurement of activity could be beneficial, such as examination of associations between physical activity levels and other symptoms. 23 The strengths of the present study included using complementary subjective and objective measurement of daytime function and sleep quality, in addition to validated questionnaires to assess multiple other symptoms in women initiating AI therapy. However, the low variability in daytime activity and sleep variables and high study discontinuation rate for factors other than toxicity limited the interpretation of the results. Accrual to the present study was slow, in part because of timing issues related to endocrine therapy initiation. Some patients had their treatment discussion with the oncologist before completing radiotherapy and were not interested in returning to the clinic to enroll in the study. Also, some patients did not want to wait an additional 10 days to wear the actigraphy device before initiating AI therapy.
Conclusion
Additional research is needed to independently validate the findings from our study and to determine why the activity levels decreased in the patients after they started AI therapy. In addition, it will be important to understand the effect of these changes in physical function and activity on adherence to, and persistence with, AI therapy. If future studies confirm the significantly reduced daytime activity in women receiving AI therapy, and, in particular, if the reduction in activity is associated with decreased therapy tolerance, intervention for patients specifically to increase their activity levels at the time of AI initiation will be warranted.
Clinical Practice Points
Although multiple studies have outlined the early-and late-onset side effects of AI therapy, to the best of our knowledge, ours is the first study to examine the sleep patterns and daytime function objectively using actigraphy and subjectively using validated questionnaires in women starting AI therapy. Daytime function was significantly reduced after 3 months of AI therapy and correlated moderately with increased fatigue. Changes in daytime function also correlated with changes in subjectively measured physical function. Further investigation is necessary to confirm these results and identify interventions to improve daytime function for women receiving AI therapy. 
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